Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Sarcoma 2Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Kidney Neoplasms 1Gliosarcoma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Bevacizumab 5pembrolizumab 3Paclitaxel 3fludarabine 2Sorafenib 2Nivolumab 2Gemcitabine 2Cyclophosphamide 2Azacitidine 2vocimagene amiretrorepvec 1ulixertinib 1temsirolimus 1sacituzumab govitecan 1ruxolitinib 1rucaparib 1regorafenib 1pazopanib 1motexafin gadolinium 1erythromycin propionate-N-acetylcysteinate 1durvalumab 1cediranib 1cc-486 1carboxyamido-triazole 1capmatinib 1belzutifan 1aflibercept 1abiraterone 1Thalidomide 1Temozolomide 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × capmatinib × Genitourinary × Clear all
NCT02386826 2023-09-21

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

SCRI Development Innovations, LLC

Phase 1 Completed
65 enrolled
CNSGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Glioblastoma, Colorectal Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡